03759 PHARMARON
- 9.990
- +0.510+5.38%
PHARMARON News
Kanglong Chemical (03759) plans to repurchase 200 million to 300 million yuan of A-shares
According to the Zhitong Finance App, Kang Long Huacheng (03759) announced that since the closing price of the company's A shares fell by more than 20% in 20 consecutive trading days as of April 19, 2024, necessary to protect the company's value and shareholders' rights and effectively promote the implementation of the “Double Improvement of Quality and Return” action plan, the company plans to use its own funds to repurchase some of the company's RMB common stock A shares through centralized bidding transactions. The total amount of capital for this repurchase is not less than RMB 200 million and no more than RMB 300 million (all inclusive), and the maximum repurchase price does not exceed
2023年度報告
Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
04:14 AM EDT, 04/29/2024 (MT Newswires) -- Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Changes in Hong Kong stocks | CRO concept stocks continue to rebound, the downstream demand side needs to improve, and domestic CXO companies still have a competitive advantage
CRO concept stocks continued to rebound. As of press release, Viva Biotech (01873) rose 8.93% to HK$0.61; Kingsley Biotech (01548) rose 8.35% to HK$11.94; Kanglong Chemical (03759) rose 5.91% to HK$10.04; and Pharmaceutical Biotech (02269) rose 5.79% to HK$14.26.
Trending Industry Today: TIGERMED Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 26th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up and TIGERMED leading Gains.$TIGERMED(03
Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 8% to lead CRO concept stocks, reports say the national level is expected to introduce an action plan for the biological manufacturing industry in the near future
CRO concept stocks increased their gains in the afternoon. As of press release, Tiger Pharmaceuticals (03347) rose 8.39% to HK$33.6; Kanglong Chemical (03759) rose 7.16% to HK$9.43; Pharmaceutical Biotech (02269) rose 6.75% to HK$13.6; and Pharmaceuticals (02359) rose 4.74% to HK$35.35.
Kanglong Chemical plans to repurchase 200 million to 300 million yuan of A shares
Kanglong Chemical (03759) announced that in order to maintain the company's value and the rights of the company's shareholders, enhance investor confidence, and comprehensively consider factors such as the company's financial situation, future development and reasonable valuation level, the company plans to use its own funds to repurchase A-shares. The repurchase price of shares shall not exceed RMB 31/share (inclusive), and the total repurchase capital shall not be less than RMB 200 million (inclusive) and not more than RMB 300 million (inclusive). The repurchase of A-shares is intended to be used to cancel and reduce the company's registered capital. According to the estimated total capital for repurchasing shares of RMB 200 million to RMB 300 million, the repurchase price of shares does not exceed RMB 300 million
Kanglong Chemical (03759) plans to repurchase 200 million to 300 million yuan of A-shares
Kanglong Chemical (03759) announced that in order to maintain the company's value and the rights of the company's shareholders and enhance investor confidence, it will comprehensively consider...
Kanglong Chemical (03759.HK) appoints Yan Luojun as company secretary
Gelonghui, April 25, 丨 Kanglong Chemical (03759.HK) announced that Ms. Mak Baowen has resigned as the company's company secretary and will no longer act as the company's authorized representative and agent for legal procedures, effective April 25, 2024. The board of directors further announced that Mr. Yan Luojun has been appointed as the company secretary, authorized representative and agent for legal proceedings, with effect from April 25, 2024.
康龍化成：2024年第一季度報告
Kanglong Chemical (300759.SZ): Net profit of 231 million yuan in the first quarter decreased by 33.80% year on year
Gelonghui, April 25 | Kanglong Chemical (300759.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 2,671 billion yuan, down 1.95% year on year; net profit attributable to shareholders of listed companies was 231 million yuan, down 33.80% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 187 million yuan, down 46.01% year on year; basic earnings per share were 0.1,300 yuan.
Trending Industry Today: GENSCRIPT BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 19th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending lower today with 9 constituents down and GENSCRIPT BIO leading Losses.$GENS
Changes in Hong Kong stocks | CRO concept stocks continue to decline, the Federal Reserve does not rule out possible interest rate hikes, domestic innovative drugs are still in an adjustment cycle
The Zhitong Finance App learned that CRO concept stocks continued to decline. As of press release, Tiger Pharmaceuticals (03347) fell 7.94% to HK$28.4; Kingsley Biotech (01548) fell 5.93% to HK$10.78; Kanglong Chemical (03759) fell 4.83% to HK$8.47; and Pharmaceuticals (02359) fell 4.5% to HK$32.9. According to the news, overnight, Federal Reserve officials made hawkish remarks. New York Federal Reserve Chairman Williams said that if the data reminds us that we need to raise interest rates to achieve our goals, then we will obviously do it. Furthermore, Asia
Kanglong Chemical (03759): The company's actual controller Lou Xiaoqiang postponed the purchase of 600,000 pledged shares
Kanglong Chemical (03759) issued an announcement. The company recently received a letter from the company's actual controller, Lou Xiaoqiang, to learn that the building...
Kanglong Chemical (300759.SZ): Revenue from North American customers accounted for 64.14% of the company's revenue in 2023
Gelonghui, April 16 | Kanglong Chemical (300759.SZ) said on the investor interactive platform that in 2023, the company's revenue from North American customers accounted for 64.14% of the company's revenue.
Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) fell more than 6%, leading the CRO concept, the possibility that the Federal Reserve will raise interest rates is still possible, and domestic innovative drugs are still in the adjustment cycle
CRO concept stocks continued to decline. As of press release, Zhaoyan Pharmaceutical (06127) fell 5.98% to HK$9.28; Tiger Pharmaceuticals (03347) fell 5.93% to HK$30.15; Kanglong Chemical (03759) fell 5.18% to HK$8.78; and Pharmaceuticals (02359) fell 3.96% to HK$32.75.
Kanglong Chemical (03759.HK) plans to hold a board meeting on April 25 to approve the first quarter results
Gelonghui, April 11, 丨 Kanglong Chemical (03759.HK) issued an announcement. The board meeting will be held on April 25, 2024 (Thursday) to review and approve (among other things) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
Kanglong Chemical (03759.HK) signed a limited partnership agreement to invest in Yongxin Kangjun Fund
Gelonghui, April 8, 丨 Kanglong Chemical (03759.HK) announced that on April 8, 2024, Kangjun Investment (as general partner) signed a limited partnership agreement with eight limited partners (i.e. the company, Beijing Xinyuan Zhikang, Ningbo Yongxin, Ningbo Yongqian, Ningbo Yongcai, Zhuhai Hi-Tech, Shanghai Southern Model and Mr. Yu Yuejiang) to invest in Yongxin Kangjun Fund. Yongxin Kangjun Fund will be registered as a limited partnership in China. The main goal is to invest in the shares, shares, and equity shares of related enterprises or other economic entities with innovative technology or innovative service platforms in the biomedical field;
Changes in Hong Kong stocks | Kanglong Chemical (03759) falls by more than 8%, leading the decline in the CRO concept stock industry's growth rate is slowing, and macro risk factors have yet to be implemented
The Zhitong Finance App learned that CRO concept stocks had the highest decline. As of press release, Kanglong Chemical (03759) fell 8.35% to HK$8.78; Zhaoyan Pharmaceutical (06127) fell 6.59% to HK$8.64; Pharmaceutical Kangde (02359) fell 6.45% to HK$36.8; and Tiger Pharmaceuticals (03347) fell 6.29% to HK$27.55. According to the news, according to the Shanghai Securities Report, CXO's leading annual reports have been released one after another recently. Judging from financial data, the performance of Yao Ming Kangde and Kanglong Chemical has achieved varying degrees of growth; in addition, Tiger Pharma's various performance indicators
Kang Long Chemical (03759)'s actual controller Lou Xiaoqiang deferred the repurchase of some of the pledged shares
According to the Zhitong Finance App, Kang Long Huacheng (03759) issued an announcement. The company recently received a letter from Mr. Lou Xiaoqiang, one of the actual controllers of the company, and learned that Mr. Lou Xiaoqiang deferred the purchase of some of the pledged shares (427,500 pledged shares) based on his capital requirements. The deferred repurchase of some of the pledged shares is a normal extension made by Mr. Lou Xiaoqiang based on the production and operation situation and capital requirements of his personal and enterprise. He has the ability to perform. The pledged shares are not at risk of liquidation, and are not burdened with performance compensation obligations such as major asset restructuring, etc., and will not have a significant impact on the company's production, operation, or corporate governance
Analysis
Price Target
No Data
